IXCLERMA Trademark Published for Opposition

The United States Patent and Trademark Office (USPTO) has published the trademark application for 'IXCLERMA' (TM79437265) for opposition. The application, filed on October 16, 2025, seeks to register the mark for a range of pharmaceutical preparations, including monoclonal antibodies for medical purposes, and treatments for arthritis, spondylitis, psoriasis, and autoimmune diseases.

This publication initiates a period during which any party believing they would be harmed by the registration of this mark can file an opposition. Companies operating in the pharmaceutical sector, particularly those developing or marketing treatments for the conditions listed, should be aware of this publication and consider whether an opposition is warranted based on existing rights or potential market confusion. No immediate compliance actions are required for entities other than potential opposers.